Methicillin Resistant Staphylococcus Aureus Drugs Market
Methicillin-resistant Staphylococcus Aureus Drugs Market Forecasts to 2030 - Global Analysis By Drug Class (Beta-lactams, Tetracyclines, Glycopeptides, Lipopeptides, Quinolones and Other Drug Classes), Route of Administration, Distribution Channel, Application, End User and By Geography
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $2.26 BN |
|
Projected Year Value (2030) |
US $3.29 BN |
|
CAGR (2023 - 2030) |
5.5% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
Asia Pacific |
|
Highest Growing Market |
Europe |
According to Stratistics MRC, the Global Methicillin-resistant Staphylococcus Aureus Drugs Market is accounted for $2.26 billion in 2023 and is expected to reach $3.29 billion by 2030 growing at a CAGR of 5.5% during the forecast period. Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium resistant to many antibiotics. They provide targeted therapy, effectively killing MRSA strains that are resistant to conventional antibiotics like methicillin. This helps prevent the spread of infections and reduces the severity of illness. They contribute to reducing the burden on healthcare systems by minimizing the need for prolonged hospital stays and costly treatments.
According to the Healthcare Cost & Utilization Project (HCUP), a family of health care databases in the U.S., the rate of deaths of hospitalized patients caused by MRSA infections is higher than non-hospitalized patients (4.7% vs. 2.1% respectively).
Market Dynamics:
Driver:
Rising incidence of MRSA infections globally
MRSA's resistance to conventional antibiotics necessitates the development and adoption of specialized medications to combat infections effectively. As MRSA infections continue to escalate worldwide, there is an increasing demand for innovative drugs tailored to address this specific bacterial strain, propelling the expansion of the MRSA drugs market as pharmaceutical companies strive to meet the growing medical needs associated with these infections.
Restraint:
Risk of adverse events
MRSA drugs carry a risk of adverse events due to their potent mechanisms and potential for causing toxicity. These adverse events can range from mild side effects to severe allergic reactions or organ damage. Such risks lead to increased caution and monitoring during treatment, impacting patient compliance and healthcare provider willingness to prescribe these drugs. Therefore, concerns about safety, efficacy, and regulatory scrutiny deter market potential.
Opportunity:
Expanding healthcare expenditure in emerging economies
Expanding healthcare expenditure in emerging economies drives the demand for better healthcare solutions, including treatments for methicillin-resistant staphylococcus aureus (MRSA). As these economies invest more in healthcare infrastructure and access, there's a greater need for effective MRSA drugs to combat the rising incidence of infections. This increased demand for MRSA drugs fuels market growth, incentivizing pharmaceutical companies to develop and supply innovative treatments.
Threat:
High drug development costs
MRSA drugs face high development costs due to the complexity of antibiotic research, stringent regulatory requirements, and the need for specialized clinical trials to demonstrate efficacy against resistant strains. These costs include extensive preclinical testing, clinical trials, and regulatory approval processes. It results in limited investment in MRSA drug development, leading to a sparse pipeline of new treatments. This scarcity hampers market growth by limiting treatment options, increasing reliance on existing therapies, and potentially exacerbating antibiotic resistance.
Covid-19 Impact
The covid-19 pandemic has indirectly affected the methicillin-resistant staphylococcus aureus drugs market. While MRSA infections remain a concern, the focus of healthcare systems has been primarily on managing the pandemic, leading to potential disruptions in the diagnosis and treatment of MRSA. Additionally, the heightened demand for antibiotics during the pandemic has impacted the usage patterns of MRSA drugs. However, the long-term impact on the MRSA drugs market will depend on factors such as healthcare infrastructure recovery and ongoing efforts to combat antibiotic resistance amidst the pandemic challenges.
The bone and joint infections segment is expected to be the largest during the forecast period
The bone and joint infections segment is estimated to have a lucrative growth. MRSA drugs play a crucial role in treating bone and joint infections by effectively targeting the resistant bacteria. These medications help mitigate the risk of complications such as osteomyelitis and septic arthritis, which can lead to significant morbidity and mortality if left untreated. By providing effective antimicrobial therapy, MRSA drugs aid in reducing inflammation, promoting healing, and preserving joint function.
The hospitals segment is expected to have the highest CAGR during the forecast period
The hospitals segment is anticipated to witness the highest CAGR growth during the forecast period. MRSA drugs play a critical role in hospital settings by effectively treating infections caused by this resilient bacterium. They help reduce morbidity and mortality rates associated with MRSA infections, safeguarding patient well-being. MRSA drugs enable healthcare providers to manage infections more efficiently, supporting better patient outcomes and contributing to the overall effectiveness of hospital infection control measures.
Region with largest share:
Asia Pacific is projected to hold the largest market share during the forecast period owing to increasing cases of MRSA infections and rising awareness about antimicrobial resistance. The market is driven by the development of novel antibiotics, government initiatives to control MRSA outbreaks, and improving healthcare infrastructure. Key players are focusing on strategic collaborations and product innovations to strengthen their market position. Overall, the MRSA drugs market in the Asia Pacific region shows promising prospects for expansion.
Region with highest CAGR:
Europe is projected to have the highest CAGR over the forecast period, owing to the high prevalence of MRSA infections and robust healthcare infrastructure. Factors such as increasing awareness about antibiotic resistance and the development of advanced treatment options contribute to market expansion. Key players in the region are actively involved in research and development efforts to introduce innovative therapies. The North American MRSA drugs market holds significant potential for further development and expansion.
Key players in the market
Some of the key players profiled in the Methicillin-resistant Staphylococcus Aureus Drugs Market include Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline PLC (GSK), Novartis AG, Allergan PLC, Bayer AG, Johnson & Johnson, Cempra Inc., Achaogen Inc., Basilea Pharmaceutica AG, Melinta Therapeutics, Paratek Pharmaceuticals, Theravance Biopharma and Tetraphase Pharmaceuticals.
Key Developments:
In October 2023, Basilea Pharmaceutica Ltd announced that it had submitted a new drug application (NDA) to the U.S. FDA for treating patients in three indications: Staphylococcus aureus bacteremia (SAB), including acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), and right-sided infective endocarditis.
In July 2021, Melinta Therapeutics launched KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that delivers a complete course of therapy for acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA).
Drug Classes Covered:
• Beta-lactams
• Tetracyclines
• Glycopeptides
• Lipopeptides
• Quinolones
• Other Drug Classes
Route of Administrations Covered:
• Oral
• Intravenous
• Topical
• Intramuscular
Distribution Channels Covered:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Applications Covered:
• Skin and Soft Tissue Infections (SSTIs)
• Hospital-acquired Pneumonia (HAP)
• Bloodstream Infections (Bacteremia)
• Bone and Joint Infections
• Other Applications
End Users Covered:
• Hospitals
• Ambulatory Surgical Centers
• Specialty Centers
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Methicillin-resistant Staphylococcus Aureus Drugs Market, By Drug Class
5.1 Introduction
5.2 Beta-lactams
5.3 Tetracyclines
5.4 Glycopeptides
5.5 Lipopeptides
5.6 Quinolones
5.7 Other Drug Classes
6 Global Methicillin-resistant Staphylococcus Aureus Drugs Market, By Route of Administration
6.1 Introduction
6.2 Oral
6.3 Intravenous
6.4 Topical
6.5 Intramuscular
7 Global Methicillin-resistant Staphylococcus Aureus Drugs Market, By Distribution Channel
7.1 Introduction
7.2 Hospital Pharmacies
7.3 Retail Pharmacies
7.4 Online Pharmacies
8 Global Methicillin-resistant Staphylococcus Aureus Drugs Market, By Application
8.1 Introduction
8.2 Skin and Soft Tissue Infections (SSTIs)
8.3 Hospital-acquired Pneumonia (HAP)
8.4 Bloodstream Infections (Bacteremia)
8.5 Bone and Joint Infections
8.6 Other Applications
9 Global Methicillin-resistant Staphylococcus Aureus Drugs Market, By End User
9.1 Introduction
9.2 Hospitals
9.3 Ambulatory Surgical Centers
9.4 Specialty Centers
9.5 Other End Users
10 Global Methicillin-resistant Staphylococcus Aureus Drugs Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Pfizer Inc.
12.2 Merck & Co. Inc.
12.3 GlaxoSmithKline PLC (GSK)
12.4 Novartis AG
12.5 Allergan PLC
12.6 Bayer AG
12.7 Johnson & Johnson
12.8 Cempra Inc.
12.9 Achaogen Inc.
12.10 Basilea Pharmaceutica AG
12.11 Melinta Therapeutics
12.12 Paratek Pharmaceuticals
12.13 Theravance Biopharma
12.14 Tetraphase Pharmaceuticals
List of Tables
1 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Region (2021-2030) ($MN)
2 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Drug Class (2021-2030) ($MN)
3 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Beta-lactams (2021-2030) ($MN)
4 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Tetracyclines (2021-2030) ($MN)
5 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Glycopeptides (2021-2030) ($MN)
6 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Lipopeptides (2021-2030) ($MN)
7 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Quinolones (2021-2030) ($MN)
8 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Other Drug Classes (2021-2030) ($MN)
9 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
10 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Oral (2021-2030) ($MN)
11 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Intravenous (2021-2030) ($MN)
12 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Topical (2021-2030) ($MN)
13 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Intramuscular (2021-2030) ($MN)
14 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
15 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
16 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
17 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
18 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Application (2021-2030) ($MN)
19 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Skin and Soft Tissue Infections (SSTIs) (2021-2030) ($MN)
20 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Hospital-acquired Pneumonia (HAP) (2021-2030) ($MN)
21 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Bloodstream Infections (Bacteremia) (2021-2030) ($MN)
22 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Bone and Joint Infections (2021-2030) ($MN)
23 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
24 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By End User (2021-2030) ($MN)
25 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
26 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
27 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Specialty Centers (2021-2030) ($MN)
28 Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
